FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  RODRIGUEZ RAUL R					2. Issuer Name <b>and</b> Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [ RIGL ]							(Check	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last)	(Firs	t)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/26/2023							X	Officer (give title below)			Other (specify below)		
RIGEL PHARMACEUTICALS, INC.												CEO, President						
611 GATEWAY BLVD, SUITE 900				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)											X	X Form filed by One Reporting Person  Form filed by More than One Reporting Person						
SOUTH SAT	· (`A	!	94080													io reperuir	g 1 010011	
(City)	(Stat	e)	(Zip)															
		-	Table I - Non	-Deriva	tive S	Securities	s Acq	uired, D	ispos	sed of	, or Benefi	cially Ow	ned					
Date					nsaction ZA. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. ) 8) 4. Securities Acquired (A) c Disposed Of (D) (Instr. 3, 4				Securities Beneficially Following F	Securities Beneficially Owned Following Reported		Direct (D) rect (I) 4)	7. Nature of Indirect Beneficial Ownership			
				Code			V A	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) f ive	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		oiration e	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Employee Stock Option (right to buy)	\$2.42	01/26/2023		A		200,000(1)		(2)	01/2	24/2032	Common Stock	200,000	\$0	400,00	00	D		

## **Explanation of Responses:**

- 1. The Reporting Person was granted an option with a performance-based condition with respect to 200,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is \$2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met.
- 2. The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met.

/s/ Raymond Furey (Attorney-in-

Fact)

\*\* Signature of Reporting Person

Date

01/30/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.